Leading Medical Imaging Company and Diagnostic Imaging Supplier Collaborate to Improve Patient Experience and Reduce Costs of Care

PRINCETON, New Jersey, December 7, 2021 / PRNewswire / – Guerbet LLC, the U.S. subsidiary of Guerbet, a global leader in medical imaging, today announced that Shields Healthcare Group, New England’s largest and most advanced diagnostic imaging provider, will present the OptiStar® Elite injection system on their network. This purchase is one of the most important in the history of Guerbet.

“Guerbet’s reputation for innovation, patient safety and excellent customer service were important considerations,” says Steve Brown, Field Service Manager of ProCare (medical equipment division of Shields). “The Guerbet team is constantly working to improve and develop new medical imaging solutions to deliver better results, better care and the best patient experience, the main reasons why this collaboration works for us. . “

The OptiStar Elite MR Contrast Delivery System offers improvements in:

  • Work flow efficiency
  • Battery-less operation
  • Possibility of filling syringes in the control room
  • Three mounting options including pedestal, ceiling and mobile

Mike Yuja, Sales Director of Guerbet at North America, says: “We are proud to partner with Shields to supply our OptiStar Elite injectors. The reliability and minimal maintenance requirements of these devices, along with the transparent installer make them an ideal choice for implementation in multiple installations.

80% of the OptiStar Elite injectors ordered have already been installed at the Shields facility in New England, with the remaining injectors installed in early 2022.

About Guerbet

At Guerbet, we build lasting relationships to enable people to live better lives. This is our goal. We are a global leader in medical imaging, offering a broad portfolio of pharmaceuticals, medical devices, digital and AI solutions for diagnostic and interventional imaging. A pioneer for 95 years in the field of contrast media with more than 2,600 people worldwide, we are constantly innovating with 10% of turnover dedicated to Research & Development and four centers in France, Israel, and United States. Guerbet (GBT) is listed on Euronext Paris (segment B – ETI) and generated € 712 million in sales in 2020. For more information, visit www.guerbet-us.com.

About OptiStar® Elite MR Contrast Delivery System

The OptiStar Elite MR Contrast Delivery System is a Class II medical device in United States. For complete information on the precautions and optimal conditions of use of this device, consult the complete user manual supplied with each device or from your local Guerbet contact (s).

Caution: Federal law in the United States restricts this device to sale by or on the order of a physician.

About Shields Healthcare Group

At Shields, improving lives and improving performance is at the heart of everything we do. That’s why more and more healthcare system leaders trust Shields to help them elevate and evolve their clinical, operational and fi nancial performance. Not just within the specialty pharmacy, but across the health care system. By working alongside your team, Shields leverages its proven collaborative care model; integrated care technologies; and dedicated teams to deliver the superior results your patients deserve and the financial results your healthcare system demands. Together, we improve performance where it matters most: expanding access to payers and medicines; improving therapeutic management and coordination of care; deliver an unmatched patient experience and generate the bottom line operating income you need to accelerate growth. Learn more about how Shields improves results and performance at shieldshealthsolutions.com.

SOURCE Guerbet

Comments are closed.